1399 related articles for article (PubMed ID: 34737215)
1. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.
Carbone C; Piro G; Agostini A; Delfino P; De Sanctis F; Nasca V; Spallotta F; Sette C; Martini M; Ugel S; Corbo V; Cappello P; Bria E; Scarpa A; Tortora G
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479922
[TBL] [Abstract][Full Text] [Related]
4. DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model.
Lei M; Liu J; Gao Y; Dai W; Huang H; Jiang Q; Liu Z
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672409
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model.
Bahwal SA; Chen JJ; E L; Hao T; Chen J; Carruthers VB; Lai J; Zhou X
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2743-2757. PubMed ID: 35556163
[TBL] [Abstract][Full Text] [Related]
6. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
7. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
8. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma.
Cannon A; Thompson CM; Maurer HC; Atri P; Bhatia R; West S; Ghersi D; Olive KP; Kumar S; Batra SK
Clin Cancer Res; 2020 Nov; 26(22):6051-6063. PubMed ID: 32873571
[TBL] [Abstract][Full Text] [Related]
9. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
10. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
11. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.
Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z; Sarmiento JM; Ahmed R; Maithel SK; El-Rayes BF; Lesinski GB
Mol Cancer Ther; 2021 Jan; 20(1):150-160. PubMed ID: 33037138
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
15. Exercise Training Improves Tumor Control by Increasing CD8
Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D
Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688
[TBL] [Abstract][Full Text] [Related]
16. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
17. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
18. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
[TBL] [Abstract][Full Text] [Related]
19. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
